ALT vs. SDGR, NAMS, APGE, BLTE, TVTX, IRON, IOVA, EVO, WVE, and PRAX
Should you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Schrödinger (SDGR), NewAmsterdam Pharma (NAMS), Apogee Therapeutics (APGE), Belite Bio (BLTE), Travere Therapeutics (TVTX), Disc Medicine (IRON), Iovance Biotherapeutics (IOVA), Evotec (EVO), Wave Life Sciences (WVE), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.
Altimmune vs.
Schrödinger (NASDAQ:SDGR) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.
Altimmune received 5 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 73.75% of users gave Altimmune an outperform vote while only 57.45% of users gave Schrödinger an outperform vote.
Schrödinger has higher revenue and earnings than Altimmune. Schrödinger is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.
Schrödinger has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500.
Schrödinger presently has a consensus price target of $32.11, suggesting a potential upside of 23.46%. Altimmune has a consensus price target of $20.83, suggesting a potential upside of 221.20%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Schrödinger.
Schrödinger has a net margin of -91.84% compared to Altimmune's net margin of -199,076.92%. Schrödinger's return on equity of -35.77% beat Altimmune's return on equity.
In the previous week, Schrödinger had 1 more articles in the media than Altimmune. MarketBeat recorded 4 mentions for Schrödinger and 3 mentions for Altimmune. Altimmune's average media sentiment score of 1.29 beat Schrödinger's score of 0.81 indicating that Altimmune is being referred to more favorably in the news media.
79.1% of Schrödinger shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 8.6% of Schrödinger shares are held by insiders. Comparatively, 4.1% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Schrödinger beats Altimmune on 9 of the 17 factors compared between the two stocks.
Get Altimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Altimmune Competitors List
Related Companies and Tools
This page (NASDAQ:ALT) was last updated on 2/18/2025 by MarketBeat.com Staff